Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.
Translational Medicine, Hospital for Sick Children Research Institute, University of Toronto, Toronto, ON, Canada.
Pediatr Surg Int. 2023 May 29;39(1):205. doi: 10.1007/s00383-023-05476-0.
Necrotizing enterocolitis (NEC) is one of the most prevalent and devastating gastrointestinal disorders in neonates. Despite advances in neonatal care, the incidence and mortality due to NEC remain high, highlighting the need to devise novel treatments for this disease. There have been a number of recent advancements in therapeutic approaches for the treatment of NEC; these involve remote ischemic conditioning (RIC), stem cell therapy, breast milk components (human milk oligosaccharides, exosomes, lactoferrin), fecal microbiota transplantation, and immunotherapy. This review summarizes the most recent advances in NEC treatment currently underway as well as their applicability and associated challenges and limitations, with the aim to provide new insight into the paradigm of care for NEC worldwide.
新生儿坏死性小肠结肠炎（NEC）是新生儿中最常见和最具破坏性的胃肠道疾病之一。尽管新生儿护理有了进步，但 NEC 的发病率和死亡率仍然很高，这凸显了需要为这种疾病设计新的治疗方法。目前，针对 NEC 的治疗方法有许多新的进展，包括远程缺血预处理（RIC）、干细胞治疗、母乳成分（人乳低聚糖、外泌体、乳铁蛋白）、粪便微生物群移植和免疫疗法。这篇综述总结了目前正在进行的 NEC 治疗方面的最新进展，以及它们的适用性和相关的挑战和局限性，旨在为全球 NEC 的护理模式提供新的见解。
